Furthering it ambition of becoming a speciality pharmaceutical company focused on respiratory diseases, UK-based pulmonary drug delivery company Vectura is to acquire Activaero in a deal worth up to €136 M (US$189 M). With the acquisition, Vectura will extend its technology offering with Activaero’s smart nebuliser-based technology Favorite® (flow and volume regulated inhalation technology). The deal will also strengthen and broaden the therapeutic focus of Vectura’s product pipeline. Activaero’s lead asset is Favolir® (nebulised budesonide by Akita® Jet), an aerosol therapy for patients with severe asthma who are dependent upon oral corticosteroids.